Works about LINAGLIPTIN
Results: 124
Author Correction: Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.944323
- By:
- Publication type:
- Article
CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial.
- Published in:
- Perspectives in Clinical Research, 2020, v. 11, n. 1, p. 44, doi. 10.4103/picr.PICR_157_19
- By:
- Publication type:
- Article
Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis.
- Published in:
- Journal of Diabetes Investigation, 2023, v. 14, n. 7, p. 844, doi. 10.1111/jdi.14017
- By:
- Publication type:
- Article
Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan.
- Published in:
- Journal of Diabetes Investigation, 2019, v. 10, n. 5, p. 1246, doi. 10.1111/jdi.13012
- By:
- Publication type:
- Article
Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
- Published in:
- Journal of Diabetes Investigation, 2019, v. 10, n. 3, p. 714, doi. 10.1111/jdi.12922
- By:
- Publication type:
- Article
Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial.
- Published in:
- Journal of Diabetes Investigation, 2018, v. 9, n. 3, p. 579, doi. 10.1111/jdi.12746
- By:
- Publication type:
- Article
Efficacy and safety comparison between pioglitazone and linagliptin in combination with metformin among patients with Type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
- Published in:
- Journal of Pharmacology & Pharmacotherapeutics, 2021, v. 12, n. 1, p. 1, doi. 10.4103/jpp.JPP_154_20
- By:
- Publication type:
- Article
Linagliptin: Cardiovascular and renal safety beyond doubt at a steep price.
- Published in:
- Journal of Pharmacology & Pharmacotherapeutics, 2020, v. 11, n. 2, p. 35, doi. 10.4103/jpp.JPP_10_20
- By:
- Publication type:
- Article
Effects of pioglitazone and linagliptin on glycemic control, lipid profile and hs-CRP in metformin-treated patients with type 2 diabetes: a comparative study.
- Published in:
- Hormone Molecular Biology & Clinical Investigation, 2023, v. 44, n. 4, p. 385, doi. 10.1515/hmbci-2022-0070
- By:
- Publication type:
- Article
The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.
- Published in:
- PLoS ONE, 2020, v. 15, n. 2, p. 1, doi. 10.1371/journal.pone.0228750
- By:
- Publication type:
- Article
New enantioselective liquid chromatography method development and validation of dipeptidyl peptidase IV inhibitors using a macrocyclic glycopeptide (vancomycin) chiral stationary phase under polar ionic mode condition.
- Published in:
- Chirality, 2022, v. 34, n. 7, p. 989, doi. 10.1002/chir.23448
- By:
- Publication type:
- Article
Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 12, p. e2244652, doi. 10.1001/jamanetworkopen.2022.44652
- By:
- Publication type:
- Article
Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 5, p. 2035, doi. 10.3390/jcm12052035
- By:
- Publication type:
- Article
Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-62579-7
- By:
- Publication type:
- Article
Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-60336-4
- By:
- Publication type:
- Article
Fixed-dose Combination of Dapagliflozin and Linagliptin in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Randomized Double-blind Multicenter Trial.
- Published in:
- Journal of Diabetology: Official Journal of Diabetes in Asia Study Group, 2025, v. 16, n. 1, p. 50, doi. 10.4103/jod.jod_169_24
- By:
- Publication type:
- Article
Journey from EMPA-REG to CARMELINA to EMPEROR-Preserved: Empagliflozin/Linagliptin in Heart Failure and Diabetes.
- Published in:
- Journal of Diabetology: Official Journal of Diabetes in Asia Study Group, 2022, v. 13, n. 3, p. 189, doi. 10.4103/jod.jod_24_22
- By:
- Publication type:
- Article
IMPURITY PROFILING STABILITY INDICATING METHOD DEVELOPMENT AND VALIDATION OF LINAGLIPTIN AND LC-MS CHARACTERIZATION OF OXIDATIVE DEGRADATION PRODUCT.
- Published in:
- Rasayan Journal of Chemistry, 2023, v. 16, n. 4, p. 2386, doi. 10.31788/RJC.2023.1648536
- By:
- Publication type:
- Article
QUANTIFICATION OF HAZARDOUS HIGH BOILING SOLVENTS IMPURITIES IN ANTI-DIABETIC DRUG LINAGLIPTIN BY NOVEL GC-ALS METHOD DEVELOPMENT AND VALIDATION.
- Published in:
- Rasayan Journal of Chemistry, 2023, v. 16, n. 3, p. 1089, doi. 10.31788/RJC.2023.1638331
- By:
- Publication type:
- Article
Efficacy and Safety of Linagliptin and Insulin in Patients of Type 2 Diabetes Mellitus with Grade 3-5 Chronic Kidney Disease in a Tertiary Care Hospital.
- Published in:
- Journal of Clinical & Diagnostic Research, 2021, v. 15, n. 8, p. 12, doi. 10.7860/JCDR/2021/50693.15204
- By:
- Publication type:
- Article
The Renoprotective Effect of Linagliptin in Type 2 Diabetic Patients with Severely Increased Albuminuria.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer's Disease.
- Published in:
- Neurochemical Research, 2023, v. 48, n. 9, p. 2714, doi. 10.1007/s11064-023-03924-w
- By:
- Publication type:
- Article
Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice.
- Published in:
- Canadian Journal of Physiology & Pharmacology, 2021, v. 99, n. 3, p. 294, doi. 10.1139/cjpp-2020-0049
- By:
- Publication type:
- Article
Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy.
- Published in:
- Pakistan Journal of Medical Sciences, 2022, v. 38, n. 1, p. 52, doi. 10.12669/pjms.38.1.4417
- By:
- Publication type:
- Article
Green and white MEKC for determination of different anti-diabetic binary mixtures and their triple-combo pill.
- Published in:
- BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-00997-0
- By:
- Publication type:
- Article
RELATIVE IN-VITRO DISSOLUTION ANALYSIS USING UV SPECTROSCOPY OF A FEW LINAGLIPTIN GENERIC TABLETS UNDER BIOWAIVER CONDITIONS.
- Published in:
- Biochemical & Cellular Archives, 2024, p. 4219, doi. 10.51470/bca.2024.24.1-S.4215
- By:
- Publication type:
- Article
Novel UV Spectroscopic Methods for Simultaneous Assessment of Empagliflozin, Linagliptin and Metformin in Ternary Mixture.
- Published in:
- Indian Journal of Pharmaceutical Education & Research, 2022, v. 56, p. S669, doi. 10.5530/ijper.56.4s.213
- By:
- Publication type:
- Article
STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF EMPAGLIFLOZIN AND LINAGLIPTIN IN PHARMACEUTICAL DOSAGE FORM.
- Published in:
- Indian Drugs, 2021, v. 58, n. 12, p. 75, doi. 10.53879/id.58.12.11916
- By:
- Publication type:
- Article
RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF LINAGLIPTIN AND EMPAGLIFLOZIN.
- Published in:
- Indian Drugs, 2019, v. 56, n. 5, p. 68, doi. 10.53879/id.56.05.11150
- By:
- Publication type:
- Article
Comparative Effectiveness of Glimepiride versus Linagliptin as add-on to Metformin in Type-2-Diabetes Mellitus.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2023, v. 13, n. 6, p. 95, doi. 10.22270/jddt.v13i6.5879
- By:
- Publication type:
- Article
Linagliptin and secoisolariciresinol diglucoside attenuate hyperlipidemia and cardiac hypertrophy induced by a high-methionine diet in rats via suppression of hyperhomocysteinemia-induced endoplasmic reticulum stress.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1275730
- By:
- Publication type:
- Article
Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin (AJU‐A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 1, p. 81, doi. 10.1111/dom.15985
- By:
- Publication type:
- Article
Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5013, doi. 10.1111/dom.15915
- By:
- Publication type:
- Article
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3064, doi. 10.1111/dom.15180
- By:
- Publication type:
- Article
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1453, doi. 10.1111/dom.14991
- By:
- Publication type:
- Article
Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 806, doi. 10.1111/dom.14636
- By:
- Publication type:
- Article
Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 115, doi. 10.1111/dom.14557
- By:
- Publication type:
- Article
Urinary dipeptidyl peptidase‐4 protein is increased by linagliptin and is a potential predictive marker of urine albumin‐to‐creatinine ratio reduction in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1968, doi. 10.1111/dom.14407
- By:
- Publication type:
- Article
Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 5, p. 1208, doi. 10.1111/dom.14317
- By:
- Publication type:
- Article
Metformin dose increase versus added linagliptin in non‐alcoholic fatty liver disease and type 2 diabetes: An analysis of the J‐LINK study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 832, doi. 10.1111/dom.14263
- By:
- Publication type:
- Article
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 569, doi. 10.1111/dom.14254
- By:
- Publication type:
- Article
Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 642, doi. 10.1111/dom.14231
- By:
- Publication type:
- Article
Validated Stability Indicating and Assay Method Development of Linagliptin in Formulation by RP-HPLC Using Quality by Design.
- Published in:
- Orbital: The Electronic Journal of Chemistry, 2020, v. 12, n. 2, p. 48, doi. 10.17807/orbital.v12i2.1194
- By:
- Publication type:
- Article
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01358-8
- By:
- Publication type:
- Article
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
- Published in:
- Cardiovascular Diabetology, 2020, v. 19, n. 1, p. 1, doi. 10.1186/s12933-020-01046-z
- By:
- Publication type:
- Article
Validated Voltammetric Method for the Simultaneous Determination of Anti‐diabetic Drugs, Linagliptin and Empagliflozin in Bulk, Pharmaceutical Dosage Forms and Biological Fluids.
- Published in:
- Electroanalysis, 2020, v. 32, n. 8, p. 1737, doi. 10.1002/elan.202000007
- By:
- Publication type:
- Article
DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1373, doi. 10.1002/ddr.21966
- By:
- Publication type:
- Article
Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study.
- Published in:
- Renal Failure, 2023, v. 45, n. 1, p. 1, doi. 10.1080/0886022X.2023.2194434
- By:
- Publication type:
- Article
The combination of linagliptin and metformin rescues bone loss in type 2 diabetic osteoporosis.
- Published in:
- Journal of Drug Targeting, 2023, v. 31, n. 6, p. 646, doi. 10.1080/1061186X.2023.2216894
- By:
- Publication type:
- Article